Evidence for Therapeutic Use of Cannabidiol for Nail-patella Syndrome-induced Pain in a Real-world Pilot Study

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 3

PMID 39627343

Authors

Thibaud Lebret

Severine Hatton

Jacques Callebert

Valerie Cormier-Daire

Celine Greco

Affiliations

Soon will be listed here.

Abstract

Nail-patella syndrome (NPS) is a rare genetic disease characterized by dysplastic nails, patella abnormalities, skeletal malformation, and chronic pain. Although chronic pain in NPS is mainly due to bone and musculoskeletal symptoms, it can also result from neurological dysfunction. Conventional analgesics are often insufficient to relieve NPS-associated chronic pain. Cannabinoids, which act on the serotonergic and/or noradrenergic pain systems, may therefore represent valuable non-psychoactive alternatives for managing pain in these patients. The effectiveness and safety of synthetic cannabidiol (CBD) for the management of NPS-associated pain was assessed using real-world data from a pilot cohort of patients with NPS who received a 3-month treatment with oral CBD. The treatment (median dose of 900 mg/day) was associated with a significant reduction in pain intensity (mean score of 7.04 ± 0.24 at initiation versus 4.04 ± 0.38 at 3 months, N = 28, p < 0.0001), which correlated with changes in the peripheral concentration of noradrenaline (r = 0.705, 95% CI [0.44-0.86], p < 0.0001). Health-related quality of life and other NPS-associated symptoms also improved in most patients. CBD treatment was well tolerated and no elevations in liver enzyme levels were reported. Synthetic CBD therefore appears to be a safe and effective treatment option for managing NPS-associated chronic pain.

References

Wever I, Largo-Barrientos P, Hoekstra E, Smidt M . Influences Correct Post-mitotic Coding of Mesodiencephalic Dopaminergic Neurons. Front Mol Neurosci. 2019; 12:62. PMC: 6427837. DOI: 10.3389/fnmol.2019.00062. View

Pertwee R . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2007; 153(2):199-215. PMC: 2219532. DOI: 10.1038/sj.bjp.0707442. View

Paul-Savoie E, Potvin S, Daigle K, Normand E, Corbin J, Gagnon R . A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin J Pain. 2011; 27(6):529-34. DOI: 10.1097/AJP.0b013e31820dfede. View

Paredes S, Cantillo S, Candido K, Knezevic N . An Association of Serotonin with Pain Disorders and Its Modulation by Estrogens. Int J Mol Sci. 2019; 20(22). PMC: 6888666. DOI: 10.3390/ijms20225729. View

Jenny M, Schrocksnadel S, Uberall F, Fuchs D . The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism. Pharmaceuticals (Basel). 2016; 3(8):2647-2660. PMC: 4033942. DOI: 10.3390/ph3082647. View

Lippacher S, Mueller-Rossberg E, Reichel H, Nelitz M . Correction of malformative patellar instability in patients with nail-patella syndrome: a case report and review of the literature. Orthop Traumatol Surg Res. 2013; 99(6):749-54. DOI: 10.1016/j.otsr.2013.03.031. View

Tayo B, Taylor L, Sahebkar F, Morrison G . A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. Clin Pharmacokinet. 2019; 59(6):747-755. PMC: 7292807. DOI: 10.1007/s40262-019-00841-6. View

Martins I, Carvalho P, de Vries M, Teixeira-Pinto A, Wilson S, Westerink B . Increased noradrenergic neurotransmission to a pain facilitatory area of the brain is implicated in facilitation of chronic pain. Anesthesiology. 2015; 123(3):642-53. DOI: 10.1097/ALN.0000000000000749. View

DAndrea G, DAmico D, Bussone G, Bolner A, Aguggia M, Saracco M . Tryptamine levels are low in plasma of chronic migraine and chronic tension-type headache. Neurol Sci. 2014; 35(12):1941-5. DOI: 10.1007/s10072-014-1867-5. View

10.

Light K, Bragdon E, Grewen K, Brownley K, Girdler S, Maixner W . Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. J Pain. 2009; 10(5):542-52. PMC: 2700184. DOI: 10.1016/j.jpain.2008.12.006. View

11.

Dai J, Johnson R, Ding Y . Manifold functions of the Nail-Patella Syndrome gene Lmx1b in vertebrate development. Dev Growth Differ. 2009; 51(3):241-50. DOI: 10.1111/j.1440-169X.2008.01083.x. View

12.

Pertwee R, Ross R, Craib S, Thomas A . (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002; 456(1-3):99-106. DOI: 10.1016/s0014-2999(02)02624-9. View

13.

Rossignol J, Hatton S, Ridley A, Hermine O, Greco C . The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study. Biomedicines. 2023; 11(2). PMC: 9953706. DOI: 10.3390/biomedicines11020520. View

14.

Witzgall R . Nail-patella syndrome. Pflugers Arch. 2017; 469(7-8):927-936. DOI: 10.1007/s00424-017-2013-z. View

15.

Haroutounian S, Arendt-Nielsen L, Belton J, Blyth F, Degenhardt L, Di Forti M . International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021; 162(Suppl 1):S117-S124. PMC: 8855877. DOI: 10.1097/j.pain.0000000000002266. View

16.

Albishri J . Arthropathy and proteinuria: nail-patella syndrome revisited. Ger Med Sci. 2014; 12:Doc16. PMC: 4235317. DOI: 10.3205/000201. View

17.

Souza J, Pacheco J, Rossi G, de-Paulo B, Zuardi A, Guimaraes F . Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics. 2022; 14(12). PMC: 9782576. DOI: 10.3390/pharmaceutics14122598. View

18.

Zhong-Qiu Zhao , Scott M, Chiechio S, Wang J, Renner K, Gereau 4th R . Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. J Neurosci. 2006; 26(49):12781-8. PMC: 6674835. DOI: 10.1523/JNEUROSCI.4143-06.2006. View

19.

Wei H, Pertovaara A . Spinal and pontine alpha2-adrenoceptors have opposite effects on pain-related behavior in the neuropathic rat. Eur J Pharmacol. 2006; 551(1-3):41-9. DOI: 10.1016/j.ejphar.2006.08.064. View

20.

Najafian B, Smith K, Lusco M, Alpers C, Fogo A . AJKD Atlas of Renal Pathology: Nail-Patella Syndrome-Associated Nephropathy. Am J Kidney Dis. 2017; 70(4):e19-e20. DOI: 10.1053/j.ajkd.2017.08.001. View